Warner Chilcott Pharmaceuticals Inc. Sustainability Profile
Warner Chilcott Pharmaceuticals Inc., a prominent player in the pharmaceutical industry, is headquartered in the United States. Founded in 2000, the company has established itself as a leader in the development and marketing of branded prescription pharmaceuticals, particularly in women's health, dermatology, and urology. With a strong operational presence across North America and Europe, Warner Chilcott is renowned for its innovative products, including contraceptives and treatments for various skin conditions. The company's commitment to quality and patient care has positioned it favourably in a competitive market, achieving notable milestones such as successful product launches and strategic partnerships. Warner Chilcott's focus on specialised therapeutic areas and its dedication to addressing unmet medical needs underscore its unique market position and ongoing contributions to healthcare.
DitchCarbon Score
How does Warner Chilcott Pharmaceuticals Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Warner Chilcott Pharmaceuticals Inc.'s score of 41 is higher than 60% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Warner Chilcott Pharmaceuticals Inc., headquartered in the US, currently does not have specific carbon emissions data available, as indicated by the absence of reported figures. The company is part of a corporate family that includes AbbVie Inc., from which it inherits climate commitments and initiatives. As a merged entity, Warner Chilcott's climate strategies and reduction targets are influenced by AbbVie Inc.'s sustainability efforts. However, no specific reduction targets or achievements have been documented for Warner Chilcott itself. The company does not appear to have set Science-Based Targets Initiative (SBTi) reduction targets or other formal climate pledges at this time. In the context of the pharmaceutical industry, companies are increasingly focusing on reducing their carbon footprints and enhancing sustainability practices. While Warner Chilcott Pharmaceuticals Inc. has not publicly disclosed its emissions data or specific commitments, it is essential for organisations in this sector to align with industry standards and pursue meaningful climate action.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2005 | 2010 | 2011 | 2012 | 2015 | 2016 | 2017 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 28,218,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 59,189,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 |
How Carbon Intensive is Warner Chilcott Pharmaceuticals Inc.'s Industry?
How Carbon Intensive is Warner Chilcott Pharmaceuticals Inc.'s Location?
Warner Chilcott Pharmaceuticals Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Warner Chilcott Pharmaceuticals Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
